Sutro Biopharma (STRO)
Market Price (11/20/2026): $8.72 | Market Cap: $144.8 MilSector: Health Care | Industry: Biotechnology
Sutro Biopharma (STRO)
Market Price (11/20/2026): $8.72Market Cap: $144.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -92% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -128% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -255% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -57%, Rev Chg QQuarterly Revenue Change % is -6.1% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -287%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -288% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113% Key risksSTRO key risks include [1] its dependence on an early-stage pipeline following the discontinuation of its previous lead program and [2] financial pressures highlighted by recent corporate restructuring and workforce reductions. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -92% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -128% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -255% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -57%, Rev Chg QQuarterly Revenue Change % is -6.1% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -287%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -288% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113% |
| Key risksSTRO key risks include [1] its dependence on an early-stage pipeline following the discontinuation of its previous lead program and [2] financial pressures highlighted by recent corporate restructuring and workforce reductions. |
Qualitative Assessment
AI Analysis | Feedback
Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined without company news as the broader market fell, tugged lower again by Nvidia. Chip and financial stocks also saw declines that day.
Down 74.5% from its Jun 29 high to Nov 18 (S&P 500 down 1.2%)
The stock declined significantly over the period, with its biggest daily drops largely coming without specific company news. The largest falls occurred on October 13, without company news, and on August 12, despite reporting encouraging early clinical activity.
Nov 13: up 2.4% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock rose following the company's report of improved net income and diluted EPS for its third quarter 2026, as losses narrowed year-over-year.
Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined without company news as the broader market fell, tugged lower again by Nvidia. Chip and financial stocks also saw declines that day.
Down 74.5% from its Jun 29 high to Nov 18 (S&P 500 down 1.2%)
The stock declined significantly over the period, with its biggest daily drops largely coming without specific company news. The largest falls occurred on October 13, without company news, and on August 12, despite reporting encouraging early clinical activity.
Nov 13: up 2.4% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock rose following the company's report of improved net income and diluted EPS for its third quarter 2026, as losses narrowed year-over-year.
Show less
Stock Movement Drivers
Fundamental Drivers
The -63.9% change in STRO stock from 7/31/2026 to 11/19/2026 was primarily driven by a -54.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312026 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.17 | 8.72 | -63.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 45 | -54.7% |
| P/S Multiple | 3.2 | 3.2 | 1.0% |
| Shares Outstanding (Mil) | 13 | 17 | -21.1% |
| Cumulative Contribution | -63.9% |
Market Drivers
7/31/2026 to 11/19/2026| Return | Correlation | |
|---|---|---|
| STRO | -63.9% | |
| Market (SPY) | -3.9% | 34.3% |
| Sector (XLV) | 9.6% | 31.3% |
Fundamental Drivers
The -76.2% change in STRO stock from 4/30/2026 to 11/19/2026 was primarily driven by a -56.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 36.62 | 8.72 | -76.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 102 | 45 | -56.0% |
| P/S Multiple | 3.1 | 3.2 | 4.7% |
| Shares Outstanding (Mil) | 9 | 17 | -48.3% |
| Cumulative Contribution | -76.2% |
Market Drivers
4/30/2026 to 11/19/2026| Return | Correlation | |
|---|---|---|
| STRO | -76.2% | |
| Market (SPY) | 0.1% | 27.9% |
| Sector (XLV) | 22.6% | 15.8% |
Fundamental Drivers
The -22.1% change in STRO stock from 10/31/2025 to 11/19/2026 was primarily driven by a -56.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.20 | 8.72 | -22.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 104 | 45 | -56.8% |
| P/S Multiple | 0.9 | 3.2 | 251.3% |
| Shares Outstanding (Mil) | 9 | 17 | -48.7% |
| Cumulative Contribution | -22.1% |
Market Drivers
10/31/2025 to 11/19/2026| Return | Correlation | |
|---|---|---|
| STRO | -22.1% | |
| Market (SPY) | 6.1% | 21.7% |
| Sector (XLV) | 25.1% | 17.5% |
Fundamental Drivers
The -68.3% change in STRO stock from 10/31/2023 to 11/19/2026 was primarily driven by a -63.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312023 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.50 | 8.72 | -68.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 57 | 45 | -20.7% |
| P/S Multiple | 2.9 | 3.2 | 9.9% |
| Shares Outstanding (Mil) | 6 | 17 | -63.6% |
| Cumulative Contribution | -68.3% |
Market Drivers
10/31/2023 to 11/19/2026| Return | Correlation | |
|---|---|---|
| STRO | -68.3% | |
| Market (SPY) | 77.5% | 24.0% |
| Sector (XLV) | 49.8% | 24.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STRO Return | -31% | -46% | -47% | -57% | -37% | -25% | -96% |
| Peers Return | 29% | 11% | -3% | -3% | 24% | 27% | 111% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| STRO Win Rate | 42% | 42% | 33% | 50% | 58% | 45% | |
| Peers Win Rate | 62% | 55% | 47% | 48% | 58% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| STRO Max Drawdown | -48% | -78% | -76% | -68% | -75% | -79% | |
| Peers Max Drawdown | -17% | -20% | -24% | -23% | -22% | -17% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PFE, JNJ, ABBV, AMGN, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/19/2026 (YTD)
How Low Can It Go
| Event | STRO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -71.9% | -18.8% |
| % Gain to Breakeven | 256.5% | 23.1% |
| Time to Breakeven | 308 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.3% | -7.8% |
| % Gain to Breakeven | 15.4% | 8.5% |
| Time to Breakeven | 6 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.8% | -9.5% |
| % Gain to Breakeven | 112.1% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.7% | -33.7% |
| % Gain to Breakeven | 84.2% | 50.9% |
| Time to Breakeven | 171 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -41.2% | -19.2% |
| % Gain to Breakeven | 70.0% | 23.8% |
| Time to Breakeven | 679 days | 105 days |
In The Past
Sutro Biopharma's stock fell -71.9% during the 2025 US Tariff Shock. Such a loss loss requires a 256.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | STRO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -71.9% | -18.8% |
| % Gain to Breakeven | 256.5% | 23.1% |
| Time to Breakeven | 308 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.8% | -9.5% |
| % Gain to Breakeven | 112.1% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.7% | -33.7% |
| % Gain to Breakeven | 84.2% | 50.9% |
| Time to Breakeven | 171 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -41.2% | -19.2% |
| % Gain to Breakeven | 70.0% | 23.8% |
| Time to Breakeven | 679 days | 105 days |
In The Past
Sutro Biopharma's stock fell -71.9% during the 2025 US Tariff Shock. Such a loss loss requires a 256.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sutro Biopharma (STRO)
Sutro Biopharma, Inc. (STRO) is a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing protein therapeutics. Leveraging its proprietary XpressCF+ platform, which integrates cell-free protein synthesis with site-specific conjugation, Sutro aims to create advanced drugs for challenging diseases. The company's primary focus areas are oncology, targeting various cancers, and autoimmune disorders.
Sutro's main product candidates are Antibody-Drug Conjugates (ADCs) currently in Phase 1 clinical trials. STRO-001 is designed to target CD74 for patients battling multiple myeloma and non-Hodgkin lymphoma. Another key candidate, STRO-002, is directed against folate receptor-alpha, intended for patients with ovarian and endometrial cancers. These ADCs represent the company's internal pipeline for specific patient populations.
Beyond its internal drug development, Sutro Biopharma also strategically partners with larger pharmaceutical companies to expand its reach and validate its technology. It holds collaboration and license agreements with Merck, focusing on cytokine derivatives for cancer and autoimmune conditions, and with Celgene Corporation, for the discovery and development of bispecific antibodies and/or ADCs within the immuno-oncology field. These partnerships broaden Sutro's potential impact across diverse therapeutic areas and patient markets.
AI Analysis | Feedback
Here are 1-3 brief analogies for Sutro Biopharma (STRO):
It's like an early-stage Moderna, but focused on creating novel protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free synthesis platform, rather than mRNA.
It's like an early-stage Seagen (a pioneer in antibody-drug conjugates), but building its next-generation ADC and protein drug pipeline with its unique cell-free synthesis platform.
It's like an innovative biotech company, similar to an early-stage Genentech or Amgen, but leveraging its unique cell-free protein synthesis platform to develop advanced protein-based medicines.
AI Analysis | Feedback
- STRO-001: An antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
- STRO-002: An antibody-drug conjugate (ADC) directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
AI Analysis | Feedback
Sutro Biopharma (STRO) sells primarily to other companies. Its major customers, based on collaboration and license agreements, include:
- Merck (MRK)
- Celgene Corporation (now part of Bristol Myers Squibb, BMY)
AI Analysis | Feedback
AI Analysis | Feedback
Jane Chung, R.Ph. Chief Executive Officer
Jane Chung was appointed Chief Executive Officer of Sutro Biopharma in March 2025. She brings over 20 years of leadership experience in the pharmaceutical and biotechnology sectors. Prior to her CEO role, she served as Sutro's President and Chief Operating Officer from December 2023, and as Chief Commercial Officer starting in August 2021. Before joining Sutro, Ms. Chung held several leadership positions at AstraZeneca, including President and General Manager of AstraZeneca Canada, and Vice President of Sales and Marketing of U.S. Immuno-Oncology. Her earlier career included commercial roles at Onyx Pharmaceuticals Inc. and Genentech, Inc. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc.
Greg Chow, M.B.A. Chief Financial Officer
Greg Chow was appointed Chief Financial Officer of Sutro Biopharma effective June 2, 2025. He has over 25 years of experience encompassing corporate finance, capital markets, investment banking, financial accounting, and drug development operations. Mr. Chow's previous roles include Chief Financial Officer and Chief Business Officer at NodThera, Chief Financial Officer at Freenome Holdings, Inc., Chief Financial Officer at Frontier Medicines Corp., and Executive Vice President and Chief Financial Officer at Aptose Biosciences, Inc. He was instrumental in financing efforts at these companies, supporting a Series F funding round for Freenome Holdings, guiding Frontier Medicines through Series B and C financings, and leading Aptose Biosciences' dual listing on Nasdaq and the Toronto Stock Exchange while helping raise over $225 million in capital. Earlier in his career, he spent fourteen years in investment banking, holding leadership positions at Wedbush Securities, RBC Capital Markets, and Wells Fargo Securities.
David Pauling, J.D., M.A. Chief Administrative Officer and General Counsel
David Pauling has served as Chief Administrative Officer and General Counsel of Sutro Biopharma since April 2025. He joined Sutro in 2011 and has held positions of increasing responsibility within the company, including Intellectual Property Counsel, Associate General Counsel, Senior Intellectual Property Counsel, and Executive Director of Legal Affairs. In his current role, he is responsible for all aspects of Sutro's legal operations, including governance, compliance, disclosure, intellectual property, and agreements. Before joining Sutro, Mr. Pauling practiced law at Jones Day and Pennie & Edmonds, LLP. He holds a J.D. from Santa Clara University School of Law, and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.
Hans-Peter Gerber, Ph.D. Chief Scientific Officer
Hans-Peter Gerber has served as Chief Scientific Officer of Sutro Biopharma since September 2023. He brings over three decades of research and development experience in oncology drug development, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies. Dr. Gerber co-founded Codeable Therapeutics in 2022 and previously served as Chief Scientific Officer and Senior Vice President at 3T Biosciences. He built the R&D organization at Maverick Therapeutics, which was acquired by Takeda in 2021, and also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021. Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, contributing to numerous IND filings and three Biologics License Applications (BLAs), including Avastin®, Mylotarg®, and Besponsa®. Dr. Gerber has contributed to the development of six of the 15 FDA-approved ADCs. He received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.
Devendra Luhar Senior Vice President, Technical Operations
Devendra Luhar currently serves as Senior Vice President, Technical Operations at Sutro Biopharma. He joined Sutro in 2016 as Senior Director of Manufacturing and was promoted to Executive Director in 2018, and later to Vice President of Manufacturing & Plant Operations in August 2020. Mr. Luhar has over 30 years of experience in biotech operations, covering manufacturing, manufacturing science and technology, engineering, and logistics. At Sutro, he has been instrumental in establishing the company's manufacturing organization and GMP compliant operations, and he is responsible for Sutro's cGMP manufacturing facility. Prior to joining Sutro, he held senior leadership positions at companies such as Boehringer-Ingelheim, Novartis, Genzyme, Arbor Vita Corporation, and Baxter BioScience. Mr. Luhar holds a B.A. in Biology from San Jose State University.
AI Analysis | Feedback
The key risks to Sutro Biopharma's business are primarily associated with the inherent challenges of drug development, intense market competition, and ongoing funding requirements.
- Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Sutro Biopharma's success is highly dependent on its product candidates proving safe and effective in clinical trials and subsequently gaining regulatory approval. All of Sutro's internal product candidates are currently in early-stage development, with STRO-001 in Phase 1 clinical trials and the company shifting focus to earlier-stage candidates like STRO-004, which is in preclinical development. There is a significant risk that positive preclinical data will not translate into clinical success in humans, and many companies in the biotechnology industry have experienced setbacks in late-stage trials despite promising early results. The process of obtaining regulatory approval is complex, time-consuming, and uncertain, and the failure of any product candidate in trials or to secure approval would materially harm the business. The effective discontinuation of luveltamab tazevibulin (formerly STRO-002) further highlights the significant challenges and high failure rates in drug development.
- Intense Competition and Market Position: Sutro Biopharma operates within the highly competitive oncology sector, specifically in the rapidly evolving field of Antibody-Drug Conjugates (ADCs). The market includes numerous established pharmaceutical companies and new entrants developing similar therapies. This crowded landscape makes it challenging for Sutro to differentiate its product candidates, especially given their early stage of development. For example, the folate receptor-alpha (FRα) targeting ADC market, which included Sutro's deprioritized luveltamab (STRO-002), is increasingly competitive with other approved products and those under development. The company's ability to successfully advance its pipeline and secure partnerships is crucial for its long-term prospects in this dynamic environment.
- Funding Requirements and Potential Dilution: As a company with no products currently on the market, Sutro Biopharma generates minimal revenue, primarily relying on collaborations, and incurs significant losses due to substantial research and development costs. Advancing its product candidates through various clinical development stages requires considerable financial resources. While the company has secured funding, there is an ongoing need for additional capital, which may be obtained through equity offerings, potentially leading to shareholder dilution. The discontinuation of a late-stage asset, such as luveltamab-T, could also impact investor confidence and make it more challenging to secure future funding or partnerships.
AI Analysis | Feedback
AI Analysis | Feedback
Sutro Biopharma (NASDAQ: STRO) develops protein therapeutics for cancer and autoimmune disorders. The addressable markets for its main product candidates are substantial and global.
STRO-001 (Antibody-Drug Conjugate targeting CD74)
- Multiple Myeloma: The global multiple myeloma market was estimated at $27.75 billion in 2024, with projections to reach approximately $49.89 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.04% from 2025 to 2034. Another source indicates the global market size was valued at $29.24 billion in 2025, and is projected to grow to $49.79 billion by 2034, exhibiting a CAGR of 6.10% during the forecast period. The 7 Major Markets (7MM) for multiple myeloma reached a value of $16.4 billion in 2023 and are projected to reach $38.1 billion by 2034, with an 8% CAGR.
- Non-Hodgkin Lymphoma (NHL): The global non-Hodgkin lymphoma therapeutics market is valued at $10.99 billion in 2025 and is predicted to increase to approximately $20.94 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. The global non-Hodgkin lymphoma treatment market size was valued at $11.59 billion in 2025 and is projected to reach $19.44 billion by 2034, exhibiting a CAGR of 6.25%.
STRO-002 (Antibody-Drug Conjugate targeting Folate Receptor-Alpha)
- Ovarian Cancer: The global ovarian cancer market was estimated at $3.83 billion in 2024 and is forecast to grow from $4.08 billion in 2025 to $6.81 billion by 2033, at a CAGR of 6.70%. Another report estimates the global market size at $3.5 billion in 2023, with a projected CAGR of 7.2% from 2024 to 2032, reaching approximately $6.5 billion by 2032. Specifically for ovarian cancer, the market is projected to reach $5.1 billion by 2032.
- Endometrial Cancers: The 7 Major Markets (7MM) for endometrial cancer reached a value of $21.4 billion in 2024 and are expected to reach $31.2 billion by 2035, exhibiting a growth rate (CAGR) of 3.52% during 2025-2035. The global endometrial cancer market is valued at $19.52 billion in 2024 and is projected to reach a value of $29.44 billion by 2035 at a CAGR of 3.80% between 2025 and 2035. Another source indicates the global endometrial cancer market size is calculated at $31.09 billion in 2025 and is expected to reach around $51.15 billion by 2034, expanding at a CAGR of 5.69% from 2025 to 2034.
AI Analysis | Feedback
Sutro Biopharma (STRO) is expected to drive future revenue growth over the next 2-3 years primarily through a combination of strategic collaborations and the advancement of its proprietary clinical pipeline. Given its status as a clinical-stage biopharmaceutical company, significant product sales within this timeframe are unlikely; instead, revenue will largely be generated from partnership activities and milestone achievements.
The key drivers of future revenue growth for Sutro Biopharma are:
- Achievement of Milestones from Existing Strategic Partnerships: Sutro Biopharma has established collaborations, notably with Astellas, that are anticipated to yield milestone payments as partnered candidates progress through development. The Astellas partnership, for instance, has a first candidate expected to enter the clinic in 2026. Additionally, the company's existing agreements with Merck and Bristol-Myers Squibb (formerly Celgene) also present opportunities for milestone payments based on research and development achievements.
- Entry into New Collaboration and Licensing Agreements: The company is actively pursuing new partnership opportunities to enhance its competitive position. New collaborations typically involve upfront payments and potential future development and regulatory milestones, which would contribute to revenue growth within the specified timeframe.
- Progress of Wholly-Owned Pipeline Candidates Through Clinical Development: While direct product sales from Sutro's wholly-owned pipeline are not expected in the near term, successful advancement of its lead programs through clinical trials can trigger significant milestone payments from existing or future partners. Specifically, STRO-004, a lead oncology candidate, is in Phase 1 with key data expected in mid-2026. Another candidate, STRO-006, an ITGB6-targeting exatecan ADC for lung cancer, is projected to have an Investigational New Drug (IND) submission in 2026. Positive clinical validation of these programs could attract new collaborations or expand existing ones, leading to revenue generation.
AI Analysis | Feedback
Share Issuance
- In February 2026, Sutro Biopharma priced an underwritten public offering of 7,868,383 shares of common stock at $13.98 per share, expecting to generate approximately $110.0 million in gross proceeds.
- In December 2025, the company implemented a 1-for-10 reverse stock split.
- In April 2024, Sutro Biopharma raised $75 million through an underwritten offering of common stock.
Inbound Investments
- Sutro Biopharma received $75 million in upfront payments and an equity investment from Ipsen in April 2024, for licensing exclusive global rights to STRO-003.
- Revenue for the year ended December 31, 2024, was $62.0 million, primarily derived from collaborations with Astellas and the Tasly agreement.
- For the year ended December 31, 2023, the company reported revenues of $153.7 million.
Outbound Investments
- In 2024, the company realized a gain of $32.1 million from the sale of Vaxcyte common stock.
Capital Expenditures
- Sutro Biopharma plans to decommission its internal GMP manufacturing facility by year-end 2025, transitioning to an external manufacturing strategy.
- Cash payments estimated to be between $40 million and $45 million are expected to result from a strategic portfolio review and related restructuring in 2025, which includes the manufacturing facility transition.
- Proceeds from the February 2026 underwritten offering are intended for general corporate purposes, including funding capital expenditures.
Peer Outperformance in Biotechnology
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| STRO | Sutro Biopharma | 46.4% | -0.9x | -4.2% | -68.5% | -95.0% | — |
| ALNY | Alnylam Pharmaceuticals | 43.6% | 7.5x | -67.9% | -10.6% | -18.3% | +77pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 5 | 20.1% | 78.5% | 200.4% | CAH 522% · MCK 393% · COR 200% |
| Health Care Services | 20 | 29.8% | 19.4% | 13.7% | RDNT 146% · HIMS 119% · DGX 92% |
| Managed Health Care | 8 | 54.9% | -10.9% | -9.1% | OSCR 154% · HQY 59% · ELV 1% |
| Health Care Facilities | 26 | 14.5% | 11.8% | -10.2% | THC 240% · NHC 208% · EHC 184% |
| Health Care Equipment | 50 | -1.7% | 2.7% | -17.2% | GKOS 395% · UFPT 330% · TMDX 313% |
| Health Care Supplies | 11 | 22.8% | -2.2% | -40.4% | LNTH 256% · HAE 114% · MMSI 22% |
| Pharmaceuticals | 60 | -15.9% | -1.5% | -42.0% | LQDA 1229% · KNSA 667% · XERS 632% |
| Life Sciences Tools & Services | 110 | -21.8% | -26.1% | -74.7% | AXGN 477% · NTRA 181% · MEDP 179% |
| Biotechnology ← | 370 | -35.1% | -42.2% | -84.4% | ELVN 1306% · TRVI 1194% · DNTH 1168% |
| Health Care Technology | 23 | -20.5% | -61.1% | -88.1% | VEEV -14% · DOCS -52% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sutro Biopharma Stock Pre-Market (+6.9%): Momentum From Analyst EPS Upgrade | 12/27/2025 | |
| Sutro Biopharma Earnings Notes | 12/16/2025 | |
| Is Sutro Biopharma Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 277.72 |
| Mkt Cap | 199.5 |
| Rev LTM | 51,264 |
| Op Inc LTM | 14,617 |
| FCF LTM | 10,684 |
| FCF 3Y Avg | 9,632 |
| CFO LTM | 13,104 |
| CFO 3Y Avg | 11,822 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.0% |
| Rev Chg 3Y Avg | 7.7% |
| Rev Chg Q | 7.2% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 25.3% |
| Op Inc Chg 3Y Avg | 14.7% |
| Op Mgn LTM | 28.3% |
| Op Mgn 3Y Avg | 25.3% |
| QoQ Delta Op Mgn LTM | 2.2% |
| CFO/Rev LTM | 27.5% |
| CFO/Rev 3Y Avg | 28.5% |
| FCF/Rev LTM | 20.6% |
| FCF/Rev 3Y Avg | 22.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs) | 102 | 62 | 154 | 68 | |
| Bristol Myers Squibb Company (BMS) | 11 | ||||
| Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name EMD Serono) | 5 | ||||
| Merck Sharp & Dohme Corporation (Merck) | 43 | ||||
| Vaxcyte, Inc. (Vaxcyte) | 3 | ||||
| Total | 102 | 62 | 154 | 68 | 62 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs) | -158 | -238 | -89 | -129 |
| Total | -158 | -238 | -89 | -129 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs) | -191 | -227 | -107 | -119 |
| Total | -191 | -227 | -107 | -119 |
Price Behavior
| Market Price | $8.72 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 09/27/2018 | |
| Distance from 52W High | -78.7% | |
| 50 Days | 200 Days | |
| DMA Price | $12.38 | $22.64 |
| DMA Trend | down | down |
| Distance from DMA | -29.6% | -61.5% |
| 3M | 1YR | |
| Volatility | 71.9% | 86.3% |
| Downside Capture | 440.38 | 138.89 |
| Upside Capture | 86.86 | 126.13 |
| Correlation (S&P 500) | 39.0% | 23.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.61 | 1.07 | 1.37 | 1.38 | 1.18 | 1.54 |
| Up Beta | -17.86 | -0.08 | 2.11 | 3.83 | 3.17 | 1.46 |
| Down Beta | -3.10 | -0.92 | -0.63 | 1.02 | 0.30 | 1.77 |
| Up Capture | -174% | -85% | -64% | -60% | 52% | 106% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 6 | 14 | 21 | 50 | 116 | 337 |
| Down Capture | 558% | 411% | 372% | 213% | 103% | 111% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 16 | 29 | 43 | 76 | 133 | 403 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STRO | |
|---|---|---|---|---|
| STRO | -2.0% | 86.3% | 0.35 | - |
| Sector ETF (XLV) | 18.3% | 17.1% | 0.80 | 18.5% |
| Equity (SPY) | 9.7% | 13.9% | 0.41 | 24.1% |
| Gold (GLD) | -10.5% | 29.0% | -0.39 | 12.6% |
| Commodities (DBC) | 28.2% | 21.5% | 1.05 | -4.2% |
| Real Estate (VNQ) | 8.8% | 14.3% | 0.34 | 6.9% |
| Bitcoin (BTCUSD) | -32.3% | 43.7% | -0.78 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STRO | |
|---|---|---|---|---|
| STRO | -46.8% | 89.9% | -0.30 | - |
| Sector ETF (XLV) | 7.7% | 15.4% | 0.30 | 26.8% |
| Equity (SPY) | 10.5% | 17.3% | 0.44 | 25.9% |
| Gold (GLD) | 14.0% | 19.2% | 0.58 | 3.1% |
| Commodities (DBC) | 6.8% | 19.6% | 0.23 | -1.9% |
| Real Estate (VNQ) | 0.7% | 19.0% | -0.07 | 20.1% |
| Bitcoin (BTCUSD) | -0.6% | 51.4% | 0.17 | 16.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STRO | |
|---|---|---|---|---|
| STRO | -24.9% | 84.9% | -0.03 | - |
| Sector ETF (XLV) | 11.5% | 16.8% | 0.56 | 31.9% |
| Equity (SPY) | 14.5% | 18.0% | 0.68 | 33.5% |
| Gold (GLD) | 10.7% | 16.6% | 0.52 | 2.6% |
| Commodities (DBC) | 7.2% | 18.2% | 0.31 | 6.2% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.23 | 26.9% |
| Bitcoin (BTCUSD) | 56.3% | 66.3% | 0.96 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/20/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2026 | 2.4% | -9.1% | |
| 8/12/2026 | -14.9% | -12.0% | -28.8% |
| 5/14/2026 | 1.4% | -20.3% | -21.4% |
| 3/23/2026 | 10.5% | 13.0% | 66.6% |
| 11/6/2025 | -13.4% | -1.4% | -9.9% |
| 8/7/2025 | 0.3% | -2.5% | 22.8% |
| 5/8/2025 | -9.1% | -8.3% | -13.7% |
| 3/13/2025 | -35.2% | -36.3% | -51.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 16 | 12 | 12 |
| # Negative | 10 | 14 | 13 |
| Median Positive | 3.8% | 13.8% | 18.5% |
| Median Negative | -6.0% | -8.7% | -13.7% |
| Max Positive | 27.8% | 55.7% | 89.9% |
| Max Negative | -35.2% | -36.3% | -51.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2026 | 2.4% | -9.1% | |
| 8/12/2026 | -14.9% | -12.0% | -28.8% |
| 5/14/2026 | 1.4% | -20.3% | -21.4% |
| 3/23/2026 | 10.5% | 13.0% | 66.6% |
| 11/6/2025 | -13.4% | -1.4% | -9.9% |
| 8/7/2025 | 0.3% | -2.5% | 22.8% |
| 5/8/2025 | -9.1% | -8.3% | -13.7% |
| 3/13/2025 | -35.2% | -36.3% | -51.8% |
| 11/13/2024 | -12.9% | -32.6% | -46.5% |
| 8/13/2024 | 11.5% | 48.1% | 38.2% |
| 5/13/2024 | 2.6% | 10.6% | -7.8% |
| 3/25/2024 | 27.8% | 55.7% | 6.1% |
| 1/8/2024 | 0.3% | 14.6% | 37.8% |
| 11/13/2023 | 14.5% | 33.8% | 89.9% |
| 8/10/2023 | -1.8% | -3.0% | 6.0% |
| 5/15/2023 | 4.3% | -4.1% | -1.6% |
| 3/30/2023 | 3.1% | 2.5% | 2.2% |
| 11/8/2022 | 2.7% | 2.5% | 10.2% |
| 8/8/2022 | 6.6% | 14.9% | -9.2% |
| 5/9/2022 | 6.0% | -5.8% | -8.2% |
| 2/28/2022 | -2.9% | -11.0% | -5.6% |
| 11/10/2021 | -0.0% | -11.9% | -31.5% |
| 8/9/2021 | -0.5% | 2.3% | 14.2% |
| 5/7/2021 | 4.2% | 1.7% | 2.5% |
| 3/18/2021 | -0.1% | -6.1% | -16.5% |
| 11/5/2020 | 3.5% | 18.6% | 62.7% |
| SUMMARY STATS | |||
| # Positive | 16 | 12 | 12 |
| # Negative | 10 | 14 | 13 |
| Median Positive | 3.8% | 13.8% | 18.5% |
| Median Negative | -6.0% | -8.7% | -13.7% |
| Max Positive | 27.8% | 55.7% | 89.9% |
| Max Negative | -35.2% | -36.3% | -51.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/12/2026 | 10-Q |
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/23/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/12/2026 | 10-Q |
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/23/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/18/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/16/2020 | 10-K |
Insider Activity
Updated 9/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gerber, Hans-Peter | CHIEF SCIENTIFIC OFFICER | Direct | Buy | 10162025 | 0.80 | 17,000 | 13,607 | 57,494 | Form |
| 2 | Chow, Gregory K | CFO | Direct | Buy | 10162025 | 0.81 | 19,750 | 15,998 | 15,998 | Form |
| 3 | Chung, Jane | Chief Executive Officer | Direct | Buy | 10162025 | 0.80 | 12,500 | 10,011 | 98,391 | Form |
| 4 | Matsui, Connie | Direct | Buy | 10162025 | 0.80 | 50,000 | 39,950 | 39,950 | Form | |
| 5 | Pauling, David | Chief Admin. Ofcr. & GC | Direct | Buy | 10162025 | 0.80 | 12,504 | 9,993 | 57,332 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gerber, Hans-Peter | CHIEF SCIENTIFIC OFFICER | Direct | Buy | 10162025 | 0.80 | 17,000 | 13,607 | 57,494 | Form |
| 2 | Chow, Gregory K | CFO | Direct | Buy | 10162025 | 0.81 | 19,750 | 15,998 | 15,998 | Form |
| 3 | Chung, Jane | Chief Executive Officer | Direct | Buy | 10162025 | 0.80 | 12,500 | 10,011 | 98,391 | Form |
| 4 | Matsui, Connie | Direct | Buy | 10162025 | 0.80 | 50,000 | 39,950 | 39,950 | Form | |
| 5 | Pauling, David | Chief Admin. Ofcr. & GC | Direct | Buy | 10162025 | 0.80 | 12,504 | 9,993 | 57,332 | Form |
Investor Activity (13F)
Updated Nov 20, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Sutro Biopharma — Investor Video Playlist






Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.